Can a new biologic clear stubborn psoriasis?
Disease control
Completed
This Phase III trial is testing an investigational biologic called LZM012 in adults with moderate-to-severe plaque psoriasis. The drug targets two inflammatory proteins, IL-17A and IL-17F, to potentially reduce skin symptoms. Participants will receive LZM012 injections, and resea…
Phase: PHASE3 • Sponsor: Livzon Pharmaceutical Group Inc. • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC